Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
08 2019
Historique:
received: 02 11 2018
revised: 28 03 2019
accepted: 28 03 2019
pubmed: 20 5 2019
medline: 18 12 2019
entrez: 20 5 2019
Statut: ppublish

Résumé

To evaluate differences in euploidy rates between IVF cycles triggered with either GnRH agonist (GnRHa) or hCG. Retrospective cohort study. University-affiliated fertility center. A total of 366 patients performing 539 IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A). Gonadotropin-releasing hormone agonist or hCG trigger of oocyte maturation during IVF cycles. Rate of euploid embryos. Patients in the GnRHa trigger arm were younger, with a lower body mass index and higher antimüllerian hormone level, and they had a higher number of oocytes retrieved and embryos biopsied. Euploid rate per embryo biopsied was higher after GnRHa trigger than after hCG trigger (37.8% ± 2.1% vs. 30.3% ± 1.8%), but multivariate regression analysis controlling for potential confounding factors did not show any differences between the two groups. Moreover, the euploid rate per oocyte retrieved was not significantly different overall (GnRHa vs. hCG: 33.9% ± 2.2% vs. 28.0% ± 1.9%). The anticipated decline in the rate of euploid embryos per oocyte retrieved went from 15.8% ± 1.2% for age <35 years to 4.3% ± 0.9% for patients aged ≥41 years. There were no significant differences between the two groups after stratifying by age and controlling for PGT-A testing modality. Both GnRHa and hCG trigger result in comparable euploid rates. Trigger with GnRHa should therefore be considered a valid option for trigger modality in freeze-all PGT-A cycles, in view of its demonstrated effectiveness and known safety enhancement.

Identifiants

pubmed: 31103285
pii: S0015-0282(19)30323-1
doi: 10.1016/j.fertnstert.2019.03.040
pii:
doi:

Substances chimiques

Chorionic Gonadotropin 0
Fertility Agents, Female 0
Gonadotropin-Releasing Hormone 33515-09-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

258-265

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Jeffrey Thorne (J)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

Alexandra Loza (A)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

Leah Kaye (L)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

John Nulsen (J)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

Claudio Benadiva (C)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

Daniel Grow (D)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.

Lawrence Engmann (L)

Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut. Electronic address: lengmann@uchc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH